The Global Health Body Sounds Alert Over Acute Scarcity of Obesity Jabs

Less than a tenth of patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, caution the global health agency as it publishes its inaugural advice on the medications.

Considering more than one billion people worldwide now obese, it is advocating for increased and just availability to GLP-1 medication.

Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.

"Our new guidance recognises that obesity is a lifelong illness that can be treated with thorough and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are key obstacles to universal access to the jabs that can assist patients in reducing substantial body mass, explains the organization.

GLP-1 Therapy Shortage

Even in the present best projected scenario, the supply of such drugs might only reach about 100 million people – less than 10% of those who need them, as stated by the health organization.

The advice encourages countries and companies to expand access, via approaches including voluntary licensing.

The intellectual property rights on semaglutide – the core ingredient of the drug Wegovy – is set to lapse in several countries in 2026.

The Way Obesity Jabs Work

These medications imitate a body's own hormone to slow digestion, curb appetite and increase satiety so individuals consume fewer calories.

Individuals commonly see weight reduction after several weeks of commencing the once-weekly jabs.

Studies points to patients may see weight return a year later of stopping the medication, as their normal food cravings resume.

Being overweight or obese elevates your chance for contracting diseases, including diabetes, heart disease, stroke, and specific malignancies.

Obesity affects individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, as per the WHO.